Clinical Trials Directory

Trials / Completed

CompletedNCT00344916

Phase 1 Study of L-NMMA in Patients With Liver Cirrhosis

NO-Synthesis in Patients With Liver Cirrhosis: Effect of L-NMMA on Renal Hemodynamics, Sodium Excretion and Plasma Levels of Vasoactive Hormones

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
30 (planned)
Sponsor
Regional Hospital Holstebro · Academic / Other
Sex
All
Age
20 Years – 60 Years
Healthy volunteers
Accepted

Summary

Phase 1 study of the effects of nitric oxide inhibition with L-NMMA in patients with liver cirrhosis and healthy controls. It is hypothesized that nitric oxide availability is increased in liver cirrhosis.

Detailed description

In a randomized, placebo controlled design the acute effects of Ng-monomethyl-L-arginine are studied on: * renal hemodynamics (GFR and RPF) * blood pressure and heart rate * lithium clearance * plasma levels of vasoactive hormones

Conditions

Interventions

TypeNameDescription
DRUGNg-monomethyl-L-arginine (drug)

Timeline

First posted
2006-06-27
Last updated
2006-07-11

Source: ClinicalTrials.gov record NCT00344916. Inclusion in this directory is not an endorsement.

Phase 1 Study of L-NMMA in Patients With Liver Cirrhosis (NCT00344916) · Clinical Trials Directory